PepGen Reports Phase 2 Myotonic Dystrophy Trial Results and $104.8 Million Cash Position

PepGen Inc. (NASDAQ:PEPG) reported third-quarter 2026 financial results alongside new Phase 2 clinical data for PGN-EDODM1, its investigational treatment for myotonic dystrophy type 1 (DM1). The biotechnology company ended September with $104.8 million in cash, cash equivalents and marketable securities, which it expects will fund operations into 2028.


The company also announced results from the 10 mg/kg dose cohort of its ongoing FREEDOM2-DM1 study, reporting improvements in RNA splicing correction and several functional assessments.

https://finviz.com/news/420311/pepgen-reports-phase-2-myotonic-dystrophy-trial-results-and-1048-million-cash-position